| HOME >> BIOLOGY >> TECHNOLOGY |
LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- RainDance Technologies, Inc., a provider of innovative droplet-based microfluidic solutions for human health and disease research, today dedicated its new headquarters and operations building and unveiled its new RDT 1000 instrument.
Keynoting the event was Sir Richard Roberts, 2003 Nobel Prize winner for physiology and medicine and Founder and Chief Scientific Officer of New England Biolabs. Chris McNary, President and Chief Executive Officer, RainDance Technologies; Daniel O'Connell, Secretary of Housing and Economic Development, Commonwealth of Massachusetts; and Robert Coughlin, President and Chief Executive Officer, Massachusetts Biotechnology Council, also spoke at the event.
"The development of new technology has driven the pace of discovery in health and human disease research," said Sir Richard Roberts. "RainDance technology has the potential to accelerate breakthroughs in genomic research and fulfill the promise of personalized medicine."
RainDance is among the first companies to relocate to Massachusetts under Governor Deval Patrick's innovative Life Sciences Initiative. The company cited the initiative as a major factor in moving the company's operations from Connecticut to Massachusetts.
"Today, our dream of bringing innovative products to market is becoming a reality here in Lexington, as we dedicate this new 28-thousand square foot facility," said Chris McNary, president and chief executive officer, RainDance Technologies. "We liked what we saw in Massachusetts. Its access to life science talent, state research grants, and the customer base of the greater Boston-Cambridge area were important requirements for our growing company," said McNary.
RainDance cited Secretary O'Connell, the Governor's Office, and the Massachusetts Biotechnology Council for making the company's relocation a smooth and seamless transition.
"Strong public-private partnerships have made Ma
'/>"/>
| SOURCE RainDance Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved |